Venous ThromboembolismODENNCT02201277
ODEN Trial: Option vs. Denali IVC Filters
A study testing Filter Placed in people with Venous Thromboembolism, run by University of California, San Francisco at 1 site in United States.
Trial summary
This research study is a prospective randomized trial evaluating the relative safety of two inferior vena cava (IVC) filters used to prevent the migration of potentially dangerous deadly blood clots from the legs to the lung in patients who cannot take blood thinners. Read more about this study
- Who is it for?
- Ages 18 years and older
- Conditions the study is for
- Venous Thromboembolism
- What is being tested?
- Filter Placed
- Type of treatment
- Medical device
- Could I receive a placebo?
- No, everyone receives an active treatment
- How many people
- 45 participants
- Where
- 1 siteUnited States
- Study dates
- 27 May 2014to 27 Apr 2018
- Phase
- Interventional
- Are there results?
- Yes, posted in the registrySummary in the doctors' view
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 years and older
- All sexes
- No healthy volunteers
- Adult, Older adult
Who may be able to join
- Patients scheduled for IVC filter placement at UCSF Moffitt, Mission Bay and Mount Zion hospitals Interventional Radiology
- 18+
Who cannot join
- Necessity of permanent IVC filter.
- Genetic or physical abnormalities of the inferior vena cava
- Circumstances that in the opinion of the primary investigator, patient would be a poor candidate either due to complications in medical condition or lack of ability for follow up.
Trial locations and contacts
1 site in 1 country.
United States1 site
UCSF Medical Center
San Francisco, California, 94143
About this study
Official title: Prospective Randomized Evaluation of the Denali and Option Inferior Vena Cava Filters
This research study is a prospective randomized trial evaluating the relative safety of two inferior vena cava (IVC) filters used to prevent the migration of potentially dangerous deadly blood clots from the legs to the lung in patients who cannot take blood thinners. All eligible patients will have been ordered to have a IVC filter placed by their primary medical team and filters will be placed in these patients whether or not they wish to participate in this trial as part of standard of care. The investigators will follow up with patients 30 days after IVC filter placement and ask them to come back for filter removal if medically appropriate. If removal is not medically appropriate in 30 days, the investigators will attempt to schedule removal every 30 days after initial placement.
Primary outcome measures will be IVC filter complications such as filter penetration through the IVC wall and into other organs, filter tilt, filter migration, filter fracture and clots formed within the filter. All of these are reported complications of all IVC filters.
Read more
The research also aims to improve the standard of care for IVC filter patient follow up as the FDA and Society of Interventional Radiology recommend that IVC filters be removed as soon as it is safe to do so.
Hypothesis:
The investigators hypothesize that there is no significant difference in efficacy and complication rate between the Option and the Denali filter.
Read the detailed description
This is a prospective, randomized trial comparing two FDA-approved inferior vena cava filters, the Denali retrievable IVC filter (Bard Peripheral Vascular Inc., Tempe, AZ) and the Option Elite (Argon Medical, Athens, Texas).
Patients scheduled for IVC filter placement at UCSF Department of Interventional Radiology (IR) will be asked by the IR physician performing the procedure at either UCSF Mt. Zion or Moffitt hospital if they wish to participate in this prospective, randomized study. Recruitment will be conducted by the physicians performing the IR procedures only. No additional recruitment calls, emails, posters or web pages are necessary. All procedures and the randomization to one of the two experimental groups will be carefully explained before obtaining signed written consent.
Screening:
Screening will be conducted by the IR physician prior to the placement of the IVC filters. Since this is a standard of care study, patients who are recommended for IVC filter placement and are scheduled for the procedure are generally eligible.
The screening procedures are part of routine care before IVC filter placement and would be done even if patients did not join the study.
The study doctor will review the results of most recent routine care imaging scans (CT or MRI) of the abdomen and pelvis. This is done to confirm that the diameter of IVC is no wider than 2.8cm. Both filters are FDA-approved to be placed in an IVC with maximal diameter of 2.8cm.
The study doctor will also review ultrasound of the lower extremity, when available, to confirm that a blood clot was in fact present prior to performing the study. This ensures that patients who present for IVC filter placement are screened properly.
The following screening procedures should be done within 12 days before the IVC filter placement procedure as part of the standard of care.
- A complete physical exam
- The study doctor will ask about medical history and how well patient is able to do daily activities
- Routine care blood tests (about 2 tablespoons) o This is to ensure that the INR and platelet count of the patient is within the safe limits to perform an invasive procedure.
After Enrollment:
If the screening procedures show that the patient is eligible and consents to take part in the study, IVC filter placement will occur after randomization.
After enrollment, the following procedures will be done during the study: Just as with screening, all of these procedures are part of regular IVC filter placement care.
Randomization:
Randomization will occur on the day of procedure or prior clinic visit with IR physician to either the Denali or Option IVC filter. All IR attending physicians on the protocol are familiar with placement of either filter type. Prior to opening study to accrual, 75 sealed security envelopes with the word Denali printed on a card inside and 75 sealed security envelopes with the word Option will be assembled by IR staff not involved in the research. The envelopes will be mixed up and placed in a bag. Computerized randomization programs and tables were considered but we feel the envelopes will work best as there may be limited time after patient is consented and procedure begins. This is especially true as some filters are placed emergently. Previous IR studies have used this randomization technique with great success.
Filter Placement:
Placement of an IVC filter involves the insertion of a plastic tube (catheter) into a vein in the neck. Some numbing medicine (Lidocaine) will be injected in the skin over the vein before the catheter is inserted. Intravenous medications will be given to induce moderate sedation (Fentanyl for analgesic and Versed for moderate sedation). Once the catheter has been placed into the vein, it will be advanced into the IVC. Once in correct position, x-ray contrast material (x-ray dye-Omnipaque 350) will be injected through the catheter and x-ray pictures taken. A series of x-ray pictures will be obtained of the IVC. These pictures are taken as part of standard of care to determine the position of the renal veins with respect to the IVC. The top of the filter must sit below the renal veins so it does not cause obstruction of the renal veins. In addition, pictures of the IVC are taken to serve as another tool in measuring the diameter of the IVC to make sure the diameter of the IVC is less than 2.8cm. This is particularly important in situations when a CT or MRI of the abdomen and pelvis is not available to have reviewed prior to the procedure. Once pictures are obtained and it is made certain that the IVC diameter is less than 2.8cm, the filter will be inserted through the catheter, and placed below the renal veins. During the placement procedure, positioning of the filter will be monitored with x-ray pictures. At the completion of the procedure the catheter will be removed and pressure will be applied to the insertion site until the bleeding has stopped. All of this is part of routine standard of care for placement of the filter. The doctor performing the procedure will be asked to complete a short questionnaire after IVC filter placement which will be attached to "Study Documents".
Follow-Up:
After the IVC filter placement procedure patient status will be followed by the interventional radiology doctors.
Per standard of care after IVC filter placement, patient will be monitored in the hospital for up to 1 hour after the procedure. If patient is in stable condition and sedation has resolved, they will return home the same day or returned to their hospital rooms.
A tentative appointment for follow up and filter retrieval will be ordered by IR physician at time of filter placement in APEX. This will ensure that scheduling and study staff will be aware that further patient and primary care follow-up is required.
Patient primary care physician and/or relevant medical staff will be telephoned one month after IVC filter placement to determine if patient is medically stable and suitable for IVC filter removal.
If IR and other doctors agree that IVC filter removal is recommended, patient will be scheduled to return for follow-up imaging and filter retrieval. If patient is not medically stable or still at high risk for blood clots, we will attempt to schedule a follow up one month later. Close contact with primary physician and patient will be maintained to ensure that filter is removed as soon as possible. APEX scheduling will be used to make sure follow up is performed at regular intervals.
At follow-up appointment these routine tests per standard of care before IVC filter removal will be performed:
- A physical exam
- The study doctor will ask about medical history, how well patient is able to do daily activities, and if they are experiencing any possible symptoms related to the IVC filter placement such as abdominal or back pain.
- A rotation CT focused to the site of the filter will be performed as part of routine practice of filter removal. This is done to ensure the filter has not migrated or that the filter has not penetrated through the walls of the IVC such that filter retrieval would be unsafe.
- IR physician will determine if patient status is stable and safe for IVC filter removal. If not, physician will discuss with primary care doctor if filter needs to remain permanently in patient or if later retrieval should be considered at subsequent follow up visits.
- IVC filter retrieval will be performed under moderate sedation. This procedure is very similar in nature to the filter placement procedure. The IVC filter is removed via a similar process to the way in which it was placed. X-ray dye (contrast) will be injected around the filter to assure that the filter and the area beneath the filter are free of blood clots and that it is safe to proceed with removal. A catheter-based snare will be used to engage the hook at the end of the filter and the filter will then be enveloped by a removal sheath and removed from the body.
- Conditions
- Venous Thromboembolism
- Being tested
- Filter Placed
- Keywords
- IVC, IVC Filter, Filter, Option, Denali, filter tilt, filter migration, filter fracture, filter thrombus, filter penetration
- Medical subject headings
- Venous Thromboembolism
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
Filter PlacedDevice
| Study group | Role | What they receive |
|---|---|---|
| Denali | Experimental | Denali IVC Filter Receives: Device: Filter Placed |
| Option | Experimental | Option Elite IVC Filter Receives: Device: Filter Placed |
What is being measured
The primary outcome is the main question the study is designed to answer.
IVC: Filter Penetration
Using imaging analysis, patients will resume their standard care as normal but be encouraged to come back in 30 days for imaging followup and removal. other than that we will look at all available CT and xray imaging that clearly shows the filter and IVC vessel walls. We will count how many participants have penetration of the IVC greater than 3mm and the number of days since placement at imaging timepoints. The number of struts or hooks per filter with penetration will also be recorded.
Measured: in dwelling time in 1 day after filter insertion up to 3 years.
Secondary outcomes (7)
Computerized Tomography (CT) Studies With IVC Penetration
All CT studies with IVC penetration ≥ 3 mm, (%)
Measured: 0-1733 days
Number of Participants With IVC Filter Migration
The number of participants with IVC filter migration in terms of distance migrated from initial placement location 30 days after filter placement will be assessed radiographically.
Measured: 30 days
IVC Filter Tilt
number of participants with tilt of greater than 15 degrees in any CT imaging studies after filter placement and before removal of filter or study endpoint reached.
Measured: 0-365 days post placement until project closure or patient endpoint reached
IVC Filter Fracture
Fracture of the component legs and struts of the IVC filter will be determined radiographically 30 days after placement.
Measured: 30 days
IVC Filter Clot
Thrombus (or clot) formed in the IVC filter 30 days after placement will be assessed radiographically.
Measured: 30 days
IVC Filter Improved Patient Follow Up and Prompt Filter Removal
The research also aims to improve the standard of care for IVC filter patient follow up as the FDA and Society of Interventional Radiology (SIR) recommend that IVC filters be removed as soon as it is safe to do so. Ideally filters will be imaged and removed after 30 days but in some cases patients will need filters to remain in place longer. We will make every effort to encourage patients and their medical team to return for follow up imaging and filter removal as soon as is deemed medically safe.
Measured: Number of participants who had filters removed after 30 days up to 1 year
IVC Filter Improved Patient Follow Up and Prompt Filter Removal: Number of Days
The research also aims to improve the standard of care for IVC filter patient follow up as the FDA and Society of Interventional Radiology (SIR) recommend that IVC filters be removed as soon as it is safe to do so. Ideally filters will be imaged and removed after 30 days but in some cases patients will need filters to remain in place longer. We will make every effort to encourage patients and their medical team to return for follow up imaging and filter removal as soon as is deemed medically safe.
Measured: Number of participants who had filters removed after 30 days up to 1 year
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted28 Jul 2014 (estimated)
- Study start27 May 2014
- Primary completion13 Apr 2018
- Study completion27 Apr 2018
Why it stopped: ODEN trial stopped due to low enrollment \& to focus on the PRESERVE Trial.
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Posted resultsParticipant flow, outcome measures and adverse events reported by the sponsor.
- Publications (1)Papers the sponsor has linked to this study.
- Other trials for Venous ThromboembolismStudies of the same condition, open and under way.
- More trials run by University of California, San FranciscoThe sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase N/A
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- Single blind
- Who is masked
- Outcomes assessor
- Enrolment
- 45 participants (actual)
Sponsor and investigators
- Lead sponsor
- University of California, San Francisco
- Sponsor type
- University, hospital or other
- Responsible party
- Sponsor
- Investigators
- Maureen P Kohi, M.D., Principal investigator, University of California, San Francisco
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT02201277
- Sponsor's protocol ID
- UCSF 14-13307
- Acronym
- ODEN
- Status last verified
- Aug 2019
- First submitted
- 23 Jul 2014
- Last updated
- 12 Sep 2019
- Results posted
- Yes, on ClinicalTrials.gov
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- Yes
Publications
Woodcock A, Campbell I, Collins JV, Hanson P, Harvey J, Corris P, Johnston ID. Bronchoscopy and infection control. Lancet. 1989 Jul 29;2(8657):270-1. doi: 10.1016/s0140-6736(89)90451-0. No abstract available.
PubMed 2569071
Study at a glance
From the registry record, last updated by the sponsor on 12 Sep 2019. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Prospective Randomized Evaluation of the Denali and Option Inferior Vena Cava Filters
- ClinicalTrials.gov ID
- NCT02201277
- Acronym / sponsor ID
- ODEN / UCSF 14-13307
- Conditions
- Venous Thromboembolism
- Keywords
- IVC, IVC Filter, Filter, Option, Denali, filter tilt, filter migration, filter fracture
- Study type
- Interventional
- Recruitment status
- TerminatedReason stopped: ODEN trial stopped due to low enrollment \& to focus on the PRESERVE Trial.
- Enrolment
- 45 participants (actual)
- Lead sponsor
- University of California, San FranciscoUniversity, hospital or other
- Study start
- 27 May 2014 (actual)
- Primary completion
- 13 Apr 2018 (actual)
- Study completion
- 27 Apr 2018 (actual)
- First posted
- 28 Jul 2014 (estimated)
- Results
- Posted 12 Sep 2019
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
This research study is a prospective randomized trial evaluating the relative safety of two inferior vena cava (IVC) filters used to prevent the migration of potentially dangerous deadly blood clots from the legs to the lung in patients who cannot take blood thinners. All eligible patients will have been ordered to have a IVC filter placed by their primary medical team and filters will be placed in these patients whether or not they wish to participate in this trial as part of standard of care. The investigators will follow up with patients 30 days after IVC filter placement and ask them to come back for filter removal if medically appropriate. If removal is not medically appropriate in 30 days, the investigators will attempt to schedule removal every 30 days after initial placement.
Primary outcome measures will be IVC filter complications such as filter penetration through the IVC wall and into other organs, filter tilt, filter migration, filter fracture and clots formed within the filter. All of these are reported complications of all IVC filters.
The research also aims to improve the standard of care for IVC filter patient follow up as the FDA and Society of Interventional Radiology recommend that IVC filters be removed as soon as it is safe to do so.
Hypothesis:
The investigators hypothesize that there is no significant difference in efficacy and complication rate between the Option and the Denali filter.
Detailed description
This is a prospective, randomized trial comparing two FDA-approved inferior vena cava filters, the Denali retrievable IVC filter (Bard Peripheral Vascular Inc., Tempe, AZ) and the Option Elite (Argon Medical, Athens, Texas).
Patients scheduled for IVC filter placement at UCSF Department of Interventional Radiology (IR) will be asked by the IR physician performing the procedure at either UCSF Mt. Zion or Moffitt hospital if they wish to participate in this prospective, randomized study. Recruitment will be conducted by the physicians performing the IR procedures only. No additional recruitment calls, emails, posters or web pages are necessary. All procedures and the randomization to one of the two experimental groups will be carefully explained before obtaining signed written consent.
Screening:
Screening will be conducted by the IR physician prior to the placement of the IVC filters. Since this is a standard of care study, patients who are recommended for IVC filter placement and are scheduled for the procedure are generally eligible.
The screening procedures are part of routine care before IVC filter placement and would be done even if patients did not join the study.
The study doctor will review the results of most recent routine care imaging scans (CT or MRI) of the abdomen and pelvis. This is done to confirm that the diameter of IVC is no wider than 2.8cm. Both filters are FDA-approved to be placed in an IVC with maximal diameter of 2.8cm.
The study doctor will also review ultrasound of the lower extremity, when available, to confirm that a blood clot was in fact present prior to performing the study. This ensures that patients who present for IVC filter placement are screened properly.
The following screening procedures should be done within 12 days before the IVC filter placement procedure as part of the standard of care.
- A complete physical exam
- The study doctor will ask about medical history and how well patient is able to do daily activities
- Routine care blood tests (about 2 tablespoons) o This is to ensure that the INR and platelet count of the patient is within the safe limits to perform an invasive procedure.
After Enrollment:
If the screening procedures show that the patient is eligible and consents to take part in the study, IVC filter placement will occur after randomization.
After enrollment, the following procedures will be done during the study: Just as with screening, all of these procedures are part of regular IVC filter placement care.
Randomization:
Randomization will occur on the day of procedure or prior clinic visit with IR physician to either the Denali or Option IVC filter. All IR attending physicians on the protocol are familiar with placement of either filter type. Prior to opening study to accrual, 75 sealed security envelopes with the word Denali printed on a card inside and 75 sealed security envelopes with the word Option will be assembled by IR staff not involved in the research. The envelopes will be mixed up and placed in a bag. Computerized randomization programs and tables were considered but we feel the envelopes will work best as there may be limited time after patient is consented and procedure begins. This is especially true as some filters are placed emergently. Previous IR studies have used this randomization technique with great success.
Filter Placement:
Placement of an IVC filter involves the insertion of a plastic tube (catheter) into a vein in the neck. Some numbing medicine (Lidocaine) will be injected in the skin over the vein before the catheter is inserted. Intravenous medications will be given to induce moderate sedation (Fentanyl for analgesic and Versed for moderate sedation). Once the catheter has been placed into the vein, it will be advanced into the IVC. Once in correct position, x-ray contrast material (x-ray dye-Omnipaque 350) will be injected through the catheter and x-ray pictures taken. A series of x-ray pictures will be obtained of the IVC. These pictures are taken as part of standard of care to determine the position of the renal veins with respect to the IVC. The top of the filter must sit below the renal veins so it does not cause obstruction of the renal veins. In addition, pictures of the IVC are taken to serve as another tool in measuring the diameter of the IVC to make sure the diameter of the IVC is less than 2.8cm. This is particularly important in situations when a CT or MRI of the abdomen and pelvis is not available to have reviewed prior to the procedure. Once pictures are obtained and it is made certain that the IVC diameter is less than 2.8cm, the filter will be inserted through the catheter, and placed below the renal veins. During the placement procedure, positioning of the filter will be monitored with x-ray pictures. At the completion of the procedure the catheter will be removed and pressure will be applied to the insertion site until the bleeding has stopped. All of this is part of routine standard of care for placement of the filter. The doctor performing the procedure will be asked to complete a short questionnaire after IVC filter placement which will be attached to "Study Documents".
Follow-Up:
After the IVC filter placement procedure patient status will be followed by the interventional radiology doctors.
Per standard of care after IVC filter placement, patient will be monitored in the hospital for up to 1 hour after the procedure. If patient is in stable condition and sedation has resolved, they will return home the same day or returned to their hospital rooms.
A tentative appointment for follow up and filter retrieval will be ordered by IR physician at time of filter placement in APEX. This will ensure that scheduling and study staff will be aware that further patient and primary care follow-up is required.
Patient primary care physician and/or relevant medical staff will be telephoned one month after IVC filter placement to determine if patient is medically stable and suitable for IVC filter removal.
If IR and other doctors agree that IVC filter removal is recommended, patient will be scheduled to return for follow-up imaging and filter retrieval. If patient is not medically stable or still at high risk for blood clots, we will attempt to schedule a follow up one month later. Close contact with primary physician and patient will be maintained to ensure that filter is removed as soon as possible. APEX scheduling will be used to make sure follow up is performed at regular intervals.
At follow-up appointment these routine tests per standard of care before IVC filter removal will be performed:
- A physical exam
- The study doctor will ask about medical history, how well patient is able to do daily activities, and if they are experiencing any possible symptoms related to the IVC filter placement such as abdominal or back pain.
- A rotation CT focused to the site of the filter will be performed as part of routine practice of filter removal. This is done to ensure the filter has not migrated or that the filter has not penetrated through the walls of the IVC such that filter retrieval would be unsafe.
- IR physician will determine if patient status is stable and safe for IVC filter removal. If not, physician will discuss with primary care doctor if filter needs to remain permanently in patient or if later retrieval should be considered at subsequent follow up visits.
- IVC filter retrieval will be performed under moderate sedation. This procedure is very similar in nature to the filter placement procedure. The IVC filter is removed via a similar process to the way in which it was placed. X-ray dye (contrast) will be injected around the filter to assure that the filter and the area beneath the filter are free of blood clots and that it is safe to proceed with removal. A catheter-based snare will be used to engage the hook at the end of the filter and the filter will then be enveloped by a removal sheath and removed from the body.
Study design
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- Single blind (outcomes assessor)
- Number of arms
- 2
| Arm | Type | Receives |
|---|---|---|
| Denali | Experimental | Device: Filter PlacedDenali IVC Filter |
| Option | Experimental | Device: Filter PlacedOption Elite IVC Filter |
Who may qualify
- Ages
- 18 years and older
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
Key inclusion criteria (2 listed)
- Patients scheduled for IVC filter placement at UCSF Moffitt, Mission Bay and Mount Zion hospitals Interventional Radiology
- 18+
Key exclusion criteria (3 listed)
- Necessity of permanent IVC filter.
- Genetic or physical abnormalities of the inferior vena cava
- Circumstances that in the opinion of the primary investigator, patient would be a poor candidate either due to complications in medical condition or lack of ability for follow up.
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| Filter Placed | Device | Denali, Option |
Primary outcome
IVC: Filter Penetration
Time frame: in dwelling time in 1 day after filter insertion up to 3 years.
Using imaging analysis, patients will resume their standard care as normal but be encouraged to come back in 30 days for imaging followup and removal. other than that we will look at all available CT and xray imaging that clearly shows the filter and IVC vessel walls. We will count how many participants have penetration of the IVC greater than 3mm and the number of days since placement at imaging timepoints. The number of struts or hooks per filter with penetration will also be recorded.
7 secondary outcomes
Computerized Tomography (CT) Studies With IVC Penetration
Time frame: 0-1733 days
Number of Participants With IVC Filter Migration
Time frame: 30 days
IVC Filter Tilt
Time frame: 0-365 days post placement until project closure or patient endpoint reached
IVC Filter Fracture
Time frame: 30 days
IVC Filter Clot
Time frame: 30 days
IVC Filter Improved Patient Follow Up and Prompt Filter Removal
Time frame: Number of participants who had filters removed after 30 days up to 1 year
IVC Filter Improved Patient Follow Up and Prompt Filter Removal: Number of Days
Time frame: Number of participants who had filters removed after 30 days up to 1 year
Results and safety
Loading the posted results from ClinicalTrials.gov…
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 12 Sep 2019.
- Posted resultsParticipant flow, baseline, all outcome measures and adverse events.
- Background: PubMed 2569071Woodcock A, Campbell I, Collins JV, Hanson P, Harvey J, Corris P, Johnston ID. Bronchoscopy and infection control. Lancet. 1989 Jul 29;2(8657):270-1. doi: 10.1016/s0140-6736(89)90451-0. No abstract available.
- ucsf radiology home pageLink provided by the sponsor.
Related trials for Venous Thromboembolism
RecruitingPhase 3
REGN7508 in Adult Participants for Prevention of Cancer-Associated Thrombosis
Cancer-Associated Thrombosis (CAT)
RecruitingPhase 3
Treatment and Secondary Prevention of Venous Thromboembolism (VTE) in Adult Participants With Solid and Hematologic Cancers
Venous Thromboembolism (VTE)
RecruitingPhase 3
REGN7508 Versus Acetylsalicylic Acid (ASA) for Venous Thromboprophylaxis After Total Knee Arthroplasty in Adult Participants
Symptomatic Venous Thromboembolism (VTE)
Recruiting
DEFIANCE: RCT of ClotTriever System Versus Anticoagulation In Deep Vein Thrombosis
Venous Thromboembolism, Deep Venous Thrombosis
RecruitingPhase 4
Aspirin vs. Rivaroxaban for Thromboprophylaxis in Multiple Myeloma
Multiple Myeloma, Venous Thromboembolism (VTE)
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
Maureen P Kohi, M.D. principal investigator
University of California, San Francisco
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A study testing Filter Placed in people with Venous Thromboembolism, run by University of California, San Francisco at 1 site in United States.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 2 inclusion and 3 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: stopped early, as of the sponsor's last update on 12 Sep 2019. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in United States. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
Yes. Results are posted in the registry (first posted 12 Sep 2019). A summary is in the For doctors view, and the full results are on ClinicalTrials.gov.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
IVC: Filter Penetration (time frame: in dwelling time in 1 day after filter insertion up to 3 years.). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
On the ClinicalTrials.gov record for NCT02201277, which also lists 1 linked publication.
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 12 Sep 2019.